Equities analysts expect Mersana Therapeutics Inc (NASDAQ:MRSN) to announce $500,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Mersana Therapeutics’ earnings, with estimates ranging from $250,000.00 to $1.00 million. Mersana Therapeutics posted sales of $1.19 million in the same quarter last year, which would indicate a negative year over year growth rate of 58%. The firm is expected to report its next quarterly earnings results on Friday, March 13th.

On average, analysts expect that Mersana Therapeutics will report full year sales of $42.38 million for the current fiscal year, with estimates ranging from $42.08 million to $43.10 million. For the next year, analysts anticipate that the firm will report sales of $1.50 million, with estimates ranging from $1.00 million to $2.50 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Mersana Therapeutics.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.02. The business had revenue of $0.84 million for the quarter, compared to the consensus estimate of $0.50 million. Mersana Therapeutics had a negative net margin of 79.49% and a negative return on equity of 41.14%.

Several brokerages have recently issued reports on MRSN. HC Wainwright raised their price objective on shares of Mersana Therapeutics from $7.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday. BidaskClub upgraded shares of Mersana Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, December 27th. Zacks Investment Research downgraded shares of Mersana Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 16th. Cowen reiterated a “buy” rating on shares of Mersana Therapeutics in a research note on Monday, January 13th. Finally, ValuEngine downgraded shares of Mersana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $10.00.

A number of institutional investors and hedge funds have recently bought and sold shares of MRSN. Boxer Capital LLC acquired a new stake in Mersana Therapeutics during the second quarter worth $8,440,000. BlackRock Inc. boosted its stake in Mersana Therapeutics by 166.2% during the second quarter. BlackRock Inc. now owns 2,390,463 shares of the company’s stock worth $9,681,000 after buying an additional 1,492,618 shares in the last quarter. Vanguard Group Inc. boosted its stake in Mersana Therapeutics by 26.9% during the second quarter. Vanguard Group Inc. now owns 1,903,502 shares of the company’s stock worth $7,709,000 after buying an additional 403,011 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Mersana Therapeutics during the second quarter worth $676,000. Finally, Millennium Management LLC boosted its stake in Mersana Therapeutics by 136.0% during the third quarter. Millennium Management LLC now owns 42,524 shares of the company’s stock worth $67,000 after buying an additional 160,624 shares in the last quarter. Hedge funds and other institutional investors own 80.37% of the company’s stock.

Shares of Mersana Therapeutics stock traded up $0.25 during midday trading on Friday, hitting $7.92. The company had a trading volume of 339,800 shares, compared to its average volume of 644,700. The business’s 50 day simple moving average is $5.41 and its two-hundred day simple moving average is $3.31. The stock has a market cap of $367.24 million, a PE ratio of -8.08 and a beta of 2.35. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.12 and a quick ratio of 5.12. Mersana Therapeutics has a 1-year low of $1.32 and a 1-year high of $8.93.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

Recommended Story: Closed-End Mutual Funds

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.